We thank Callegan and colleagues for their interest in our study. As
reflected in their letter, the role of corticosteroids in the treatment of
endophthalmitis remains controversial.
As Callegan and colleagues are aware, in some cases the review process
precludes identification of all relevant articles prior to the date of publication.
Of the 5 citations they mentioned as not cited in our study, 1 dealt with
endophthalmitis caused by a toxin-producing bacterium. This article underscores
the importance of toxins in infectious disease but covers Enterococcus faecalis, not Bacillus strains.1
Two of the cited omissions were likely published after our submission.2,3 In the article by Yoshizumi et
al,4 there was a positive response to dexamethasone
sodium phosphate treatment for experimental Staphylococcus aureus
endophthalmitis, so we do not feel that this represents an omission in stating
a contrary viewpoint. We appreciate Callegan and colleagues bringing several
of these valuable citations to the public's attention, especially the one
by Meredith et al5 that was not cited in
our original article.
Liu S, Steidl SM. Corticosteroid and Antibiotic Therapy for Bacillus Endophthalmitis. Arch Ophthalmol. 2001;119(9):1392-1393. doi: